Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 29, Issue 2, 2002, Pages 171-188

  Panetta, J C ^a   Wilkinson, M ^a   Pui, C H ^a   Relling, M V ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Bayesian methods; Etoposide; Limited sampling strategies; Monte Carlo simulation; Optimal sampling strategies; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; ETOPOSIDE; ETOPOSIDE CATECHOL; UNCLASSIFIED DRUG;

ACCURACY; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CHILD; CHILDHOOD LEUKEMIA; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; HUMAN; INTERMETHOD COMPARISON; LINEAR REGRESSION ANALYSIS; MONTE CARLO METHOD; PREDICTION; PRIORITY JOURNAL; VARIANCE;

ANALYSIS OF VARIANCE; AREA UNDER CURVE; BAYES THEOREM; CATECHOLS; CHILD; ETOPOSIDE; HUMANS; LEUKEMIA; LINEAR MODELS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; STATISTICS, NONPARAMETRIC;

EID: 0036553383     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1019755608555     Document Type: Article

References (24)

1. B. Desoize, F. Marechal, and A. Cattan. Clinical pharmacokinetics of etoposide during 120 hr continuous infusions in solid tumours. Br. J. Cancer 62:840-841 (1990).
2. M. V. Relling, H. McLeod, L. Bowman, and V. M. Santana, Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin. Pharmacol. Ther. 56:503-511 (1994).
3. K. Kobayashi and M. J. Ratain. Pharmacodynamics and long-term toxicity of etoposide. Cancer Chemother. Pharmacol. 34 Suppl.:S64-8
4. D. S. Sonnichsen, R. C. Ribeiro, X. Luo, P. Mathew, and M. Relling, Pharmacokinetics and pharmacodynamics of 21 day continuous oral etoposide in pediatric solid tumor patients. Clin. Pharmacol. Ther. 58:99-107 (1995).
5. H. Minami, M. J. Ratain, Y. Ando, and K. Shimokata. Pharmacodynamic modeling of prolonged administration of etoposide. Cancer Chemother. Pharmacol. 39:61-66 (1996).
6. D. Gentili, M. Zucchetti, V. Torri, C. Sessa, J. de Jong, F. Cavalli, and M. D'Incalci. A limited sampling model for the pharmacokinetics of etoposide given orally. Cancer Chemother. Pharmacol. 32:482-486 (1993).
7. B. Tranchand, C. Amsellem, E. Chatelut, G. Freyer, A. Iliadis, B. Ligneau, V. Trillet-Lenoir, P. Canal, I. Lochon, and C. J. Ardiet. A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother. Pharmacol. 43:316-322 (1999).
8. J. B. Holz, H. Koppler, L. Schmidt, H. W. Fritsch, K. H. Pfluger, and H. Jungclas. Limited sampling models for reliable estimation of etoposide area under the curve. Eur. J Cancer 31A:1794-1798 (1995).
9. B. L. Lum, K. J. Lane, T. W. Synold, A. Goram, S. B. Charnick, and B. I. Sikic, Validation of a limited sampling model to determine etoposide area under the curve. Pharmacotherapy 17:887-890 (1997).
10. max: a computer simulation analysis. Int. J Clin. Pharmacol. Ther. 37:439-445 (1999).
11. E. Walter and L. Pronzato. Optimal experiment design for nonlinear models subject to large prior uncertainties. Am. J Physiol. 253:R530-R534 (1987).
12. D. Z. D'Argenio. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. Math. Biosci. 99:105-118 (1990).
13. E. Walter and L. Pronzato. Qualitative and quantitative experiment design for phenomenological models - A survey. Automatica 26:195-213
14. G. D. Swanson. On the single-point, single-dose problem. In: Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis. Plenum Press, New York, 129-135 (1991)
15. Y. Merle and F. Mentre. Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model. J. Pharmacokinet. Biopharm. 23:101-125 (1995).
16. Y. Merle and F. Mentre. Stochastic optimization algorithms of a Bayesian design criterion for Bayesian parameter estimation of nonlinear regression models: application in pharmacokinetics. Math. Biosci. 144:45-70 (1997).
17. D. Z. D'Argenio. Optimal sampling times for pharmacokinetic experiments. J. Pharmacokinet. Biopharm. 9:739-756 (1981).
18. G. E. P. Box and H. L. Lucas, Design of experiments in nonlinear situations. Biometrika 46:77-90 (1959).
19. D. Z. D'Argenio and A. Schumitzky. ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software (1997).
20. J. Boos, E. Real, P. Schulze-Westhof, J. Wolff, T. Euting, and H. Jürgens. Investigation of the variability of etoposide pharmacokinetics in children. Int. J. Clin. Pharmacol. Ther.-Toxicol. 30:495-497 (1992).
21. M. V. Relling, Y. Yanishevski, J. Nemec, W. E. Evans, J. M. Boyett, F. G. Behm, and C. H. Pui. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 12:346-352 (1998).
22. S. P. Lowis, A. D. J. Pearson, D. R. Newell, and M. Cole, Etoposide pharmacokinetics in children: The development and prospective validation of a dosing equation. Cancer Res. 53:4881-4889 (1993).
23. X. Cai, M. H. Woo, M. J. Edick, and M. V. Relling, Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B. Biomed. Sci. Appl. 728:241-250 (1999).
24. L. B. Sheiner and S. L. Beal, Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9:503-512 (1981).